Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease

@article{Theleritis2017PharmacologicalAN,
  title={Pharmacological and Nonpharmacological Treatment for Apathy in Alzheimer Disease},
  author={Christos Theleritis and Kostas Siarkos and Everina A Katirtzoglou and Antonios Politis},
  journal={Journal of Geriatric Psychiatry and Neurology},
  year={2017},
  volume={30},
  pages={26 - 49}
}
Objective: Apathy is one of the most frequent neuropsychiatric symptoms encountered in Alzheimer disease (AD). Early diagnosis and timely treatment of apathy in AD seem to be of great importance, since apathy has been associated with poor disease outcome, reduced daily functioning, and caregiver distress. Design: Within this context, we conducted an extensive electronic search from the databases included in the National Library of Medicine as well as PsychInfo and Google Scholar for studies… Expand
Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer’s Disease: A Systematic Review
TLDR
Acetylcholinesterase inhibitors, gingko biloba, and methylphenidate were found to be successful in reducing apathy in patients with AD. Expand
Pharmacologic Approaches for the Management of Apathy in Neurodegenerative Disorders
TLDR
Current main levels of evidence have been reported so far with cholinergic, glutamatergic and dopaminergic agents to reduce levels of apathy, despite several conflicting results. Expand
Apathy as a Treatment Target in Alzheimer's Disease: Implications for Clinical Trials.
  • M. Mortby, L. Adler, +13 authors C. Theleritis
  • Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2021
TLDR
A comprehensive review and critical evaluation of recent advances was conducted to determine the evidence-based suggestions for future trial designs and better understanding of the subdomains and biological mechanisms of apathy. Expand
Revisiting Apathy in Alzheimer's Disease: From Conceptualization to Therapeutic Approaches
TLDR
It is unlikely that a single pharmacological or nonpharmacological strategy will be effective for all cases of apathy in AD, and high-quality evidence research is needed to better understand the role of specific strategies aiming at a personalized approach. Expand
Commentary on Apathy as a Model for Investigating Behavioral and Psychological Symptoms in Dementia
TLDR
A conceptual framework to guide thinking and research on apathy is described and has clear potential to serve as a much-needed exemplar for advancing a more integrated biopsychosocial research agenda in response to the bioppsychosocial etiology of apathy and, possibly, other BPSDs. Expand
The Effectiveness of Non-Pharmacological Interventions on Apathy in Patients With Dementia: A Systematic Review of Systematic Reviews.
TLDR
Among all the non-pharmacological interventions involved in this review, the effectiveness of multisensory stimulation, music therapy, cognitive stimulation, and pet therapy was relatively robust, and was deemed the most helpful according to evidences available. Expand
Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USA
TLDR
Current literature on the medication management of neuropsychiatric symptoms of dementia in the USA is described and approaches to and concerns about the pharmacological treatment of NPS are highlighted. Expand
Association Between CSF Beta-Amyloid and Apathy in Early-Stage Alzheimer Disease
TLDR
The CSF A β42 concentrations were negatively correlated with apathy scores and patients with severe apathy had significantly lower Aβ42 levels compared to nonapathetic ones, encouraging further studies to untangle the potential association between the complex pathophysiological dynamics of AD and apathy. Expand
State of the Science: Apathy As a Model for Investigating Behavioral and Psychological Symptoms in Dementia
TLDR
A current conceptual model of the factors contributing to BPSDs is modified to examine determinants of apathy, providing a more complete and theoretically informed understanding of apathetic, allowing for greater insight into potential targets for research, intervention, and care. Expand
Neuroanatomical Abnormalities in Older Depressed Adults With Apathy: A Systematic Review
TLDR
Apathy in late-life depression appears to be accompanied by neuroanatomical abnormalities in the salience and reward networks, which are consistent with that observed in individuals presenting with apathy in other aging-related conditions. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 162 REFERENCES
Apathy in Neurodegenerative Diseases
TLDR
Recommendations address clarification of the targeted study population, confounding factors, Mood/cognition, behavior, and treatment, outcome measures, study duration, use of comparators and considerations around environment, and the role of the caregiver and patient assent. Expand
Apathy Treatment in Alzheimer's Disease: Interim Results of the ASCOMALVA Trial.
TLDR
The combination ofdonepezil with choline alphoscerate is more effective than donepezil alone in countering symptoms of apathy in AD, which suggests that the availability in brain of a higher amount of acetylcholine could affect apathetic in AD subjects with spared executive functions. Expand
A review of neuroimaging findings of apathy in Alzheimer's disease
TLDR
Neuroimaging findings lend support to the notion that frontal-subcortical networks are involved in the occurrence of apathy in AD and reveal disease patterns, helping to distinguish clinically distinct cognitive syndromes, and allowing predictions. Expand
Pharmacological Treatment of Apathy in Neurodegenerative Diseases: A Systematic Review
TLDR
There is as yet insufficient evidence that pharmacological treatment improves apathetic symptoms in patients with neurodegenerative disease, and large-scale, placebo-controlled RCTs with apathy as a primary outcome measure are needed to establish the potential benefit of pharmacological treated apathy. Expand
Apathy in Alzheimer's Disease
TLDR
Assessment of apathy in Alzheimer's disease requires clinicians to distinguish loss of motivation from loss of ability due to cognitive decline, and current research has shown apathy to be a discrete syndrome. Expand
The Efficacy of Nonpharmacological Treatment for Dementia-related Apathy
TLDR
A structured, nonpharmacological, short-term occupational therapy intervention is more useful than activities of the patients' own choice for improving apathy in patients with mild or moderate dementia. Expand
Treating Apathy in Alzheimer’s Disease
  • P. Boyle, P. Malloy
  • Medicine, Psychology
  • Dementia and Geriatric Cognitive Disorders
  • 2003
TLDR
The assessment and treatment of apathy in AD is reviewed, with emphasis on the utility of acetylcholinesterase inhibitors and the potential benefits of other pharmacologic agents and combined pharmacologic-behavioral interventions. Expand
Pharmacologic treatment of apathy in dementia.
TLDR
A systematic literature review of studies that used apathy outcome scales to document results of pharmacologic treatments for apathy found limited evidence of efficiency of pharmacotherapy for treatment of apathy in dementia, and recommendations for standardizing research and holistic evaluation and treatment are provided. Expand
Methylphenidate for apathy and functional status in dementia of the Alzheimer type.
  • P. Padala, W. Burke, +4 authors F. Petty
  • Psychology, Medicine
  • The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry
  • 2010
TLDR
Methylphenidate was well tolerated in these patients with DAT and apathy improved with the use of methylphenidate, and there was no correlation between changes in the AES and depression scores. Expand
Donepezil for the treatment of behavioral disturbances in Alzheimer's disease: a 6-month open trial.
TLDR
Significant reduction in the presence of delusions, irritability/lability and disinhibition were achieved after 24 weeks of donepezil treatment, and the drug was well tolerated and all patients completed the study. Expand
...
1
2
3
4
5
...